Emergent BioSolutions

491 articles with Emergent BioSolutions

• Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months

  8/17/2020

  Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has approved the extension of the shelf life of NARCAN® Nasal Spray from 24 months to 36 months.

• Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028

  8/7/2020

  Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 million in aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Notes”). The Notes are fully and unconditionally guaranteed on a senior unsecured basis by all of the Company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. The Company has used the

• Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028

  8/4/2020

  Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the “Notes”), representing an increase of $50 million in aggregate principal amount from the initially proposed offering size.

• Emergent BioSolutions Announces Proposed Offering of $400 Million of Senior Unsecured Notes

  8/4/2020

  Emergent BioSolutions Inc. announced that it intends to offer $400 million aggregate principal amount of senior unsecured notes with an expected maturity date of August 2028.

• Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance

  7/30/2020

  Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the three and six months ended June 30, 2020 and revised upward full year 2020 guidance.

• 

  Emergent BioSolutions, AstraZeneca Expand COVID-19 Vaccine Manufacturing Agreement

  7/27/2020

  Gaithersburg, Maryland-based Emergent BioSolutions inked another manufacturing agreement to support the development of a vaccine against COVID-19, the disease caused by the novel coronavirus.

• Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate

  7/27/2020

  Emergent BioSolutions Inc. announced that it has signed an agreement to provide contract development and manufacturing services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

• Emergent BioSolutions Inc. to be Added to the S&P MidCap 400 Index

  7/21/2020

  Emergent BioSolutions Inc. (NYSE: EBS) today announced that Standard & Poor’s (S&P) has indicated that the company will be added to the S&P MidCap 400® index, effective prior to the open of trading on Friday, July 24.

• Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020

  7/16/2020

  Emergent BioSolutions Inc. will host a conference call on Thursday, July 30, 2020 at 5:00 pm to discuss the financial results for the second quarter of 2020, recent business developments, revenue guidance for the third quarter of 2020, and financial outlook for full year 2020.

• Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding

  7/8/2020

  Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense

• Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate   

  7/6/2020

  Emergent BioSolutions Inc. announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology.

• 

  Emergent and J&J Ink 5-Year COVID-19 Vaccine Manufacturing Deal

  7/6/2020

  Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.
• 

  Biopharma Update on the Novel Coronavirus: July 6

  7/6/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.

• Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability

  6/18/2020

  Emergent BioSolutions announced that it will further strengthen its contract development and manufacturing capabilities by expanding into viral vector and gene therapy.

• Emergent BioSolutions to Participate in Virtual Investor Conferences

  6/16/2020

  Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following virtual investor conferences this month:

• 

  Biopharma Update on the Novel Coronavirus: June 12

  6/12/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.

• Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate

  6/11/2020

  Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidate Agreement valued at approximately $87 million GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it will deploy its molecule-to-market contract development and manufacturing (CDMO) services to support the manufacturing of AstraZeneca’s vaccine candidate for

• 

  Emergent BioSolutions Joins Operation Warp Speed for COVID-19 Vaccine Development

  6/2/2020

  Emergent BioSolutions, a contract development and manufacturing organization, announced it had signed a public-private partnership under Operation Warp Speed worth about $628 million.
• 

  Biopharma Update on the Novel Coronavirus: June 2

  6/2/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.

• Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

  6/1/2020

  Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021